Physician profile
Ravi Botla
NPI 1366540544
$2,663.24
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $60.65 · 2021: $484 · 2022: $621 · 2023: $817 · 2024: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $959.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.71 | 2019-2023 | Rinvoq, Linzess, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.21 | 2019-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $269.05 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $208.20 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $170.17 | 2019-2024 | Livdelzi |
| Axonics, INC. | $116.19 | 2023 | Axonics |
| Janssen Biotech, INC. | $91.59 | 2019-2023 | Stelara |
| Celgene Corporation | $49.13 | 2023-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $44.68 | 2023 | |
| Ferring Pharmaceuticals INC. | $35.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.07 | 2019-2022 | |
| Lilly USA, LLC | $17.82 | 2023 | |
| Shionogi INC | $17.11 | 2019 | |
| Redhill Biopharma INC. | $15.70 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.70 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $14.21 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.33 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Botla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.